IDH
First-in-Class Dual PIM/FLT3 Kinase Inhibitor SEL24/MEN1703 Demonstrates Single-Agent Activity in AML
Kerri FitzgeraldAcute Myeloid Leukemia | February 2, 2023
DIAMOND-01 determined a recommended dose of SEL24/MEN1703 125 mg orally once daily for 14 days during a 21-day cycle.
Read More
Phase III Trial Shows Ivosidenib Plus Azacitidine Provided Clinical Benefit in Patients with IDH1-Mutated AML
Kerri FitzgeraldAcute Myeloid Leukemia | February 2, 2023
Event-free survival was longer in patients treated with ivosidenib plus azacitidine compared with placebo plus azacitidine.
Read More
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Editorial Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |